Levroxa 250mg Tablet contains Levetiracetam 250mg, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. This medication is commonly prescribed as adjunctive therapy or monotherapy depending on clinical presentation and patient response. Levroxa is rapidly absorbed following oral administration, with peak plasma concentrations achieved within one hour, and exhibits linear pharmacokinetics. It is primarily eliminated unchanged via renal excretion; hence, dose adjustments may be necessary in patients with impaired renal function. Common adverse effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or agitation, which typically diminish with continued use. Caution is advised in patients with a history of psychiatric disorders or suicidal ideation. Levroxa should be used under strict medical supervision, with regular monitoring to assess therapeutic efficacy and tolerability. Patients are advised not to discontinue therapy abruptly to avoid increased seizure risk. This medication is contraindicated in individuals with known hypersensitivity to Levetiracetam or any of its excipients.